HEALTHSTAT NEWS
STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial
Otsuka's Voyxact slowed kidney function loss in IgA nephropathy patients by 3 points annually versus 7.6 points with placebo in a Phase 3 trial, but the effect was less than expected. The drug's performance left room for competing treatments to outperform.
Related Signal
Adjacent reporting
- Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
- A common constipation drug shows surprising power to protect kidneys
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
- STAT+: Johnson & Johnson advances IBD therapy, despite trial miss
- STAT+: Closely watched experimental Parkinson’s drug fails key clinical trial
- Chinese drug reduces lung cancer death risk by 34% in trial